undamentalytics Newsletter
Sign in

Outlook Therapeutics, Inc. (OTLK) stock

Add to watchlist

Add holding +

NASDAQ: OTLK Nasdaq Biotechnology Next results ~November 9, 2026

Outlook Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Outlook Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders8 buying, 0 selling10 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds46 adding, 20 cuttingOf 7 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Outlook Therapeutics files

Where Outlook Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $8m, up 163.8% on a year earlier, against a decline of 41.3% a quarter earlier. Free-cash-flow margin rose to -401.8% from -1160.2% a year earlier. Operating margin widened to -445.6% from -960.1%. It passes 1 of our 2 financial-health checks.

Our model value for Outlook Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 18, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Revenue growth accelerating: TTM revenue growth rose to 163.8% (+205.1pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 163.8% over the last 12 months.
  • Growth speeding up. The growth rate is 205.1 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 514.5 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -445.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -401.8% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 16.1% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 20.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 152% and a beta of 1.1 against the S&P 500.

Latest results: FY2025 Q4

Filed December 19, 2025
Earnings per share
-$0.09 against an average estimate of -$0.07: missed by 20.0%
Share reaction
-24.4% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500
Next report
August 14, 2026; average EPS estimate -$0.07

Outlook Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.9%
  • 1 week-13.2%
  • 1 month-22.4%
  • This year-70.3%
  • 1 year-64.6%
  • 5 years-98.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-2.15

Cash

Free cash flow (TTM)
-$56.2M

Earnings

Last results
August 14, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Announcement
  4. Results
  5. Results
  6. Insider trade
  7. Announcement
  8. Leadership
  9. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Outlook Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192025
Share price$680.00$219.20$156.80$29.80$1.06
Market value$585m$263m$309m$27m$37m
+ Net debt (− = net cash)$5m$2m$3m−$8m$22m
Enterprise value$590m$265m$312m$19m$59m
Multiples
Price / sales 196.4x69.1x100.2x3.3x26.1x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.43 +77% $682670 −52%
Next −$0.12 +72% $44m +6356%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −14.7% on 90 days ago. In the last 30 days, 2 analysts raised Outlook Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Outlook Therapeutics, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.51 Current fiscal year, 60 days ago: −$0.51 Current fiscal year, 30 days ago: −$0.49 Current fiscal year, 7 days ago: −$0.42 Current fiscal year, Now: −$0.43 −$0.43 Next fiscal year, 90 days ago: −$0.22 Next fiscal year, 60 days ago: −$0.22 Next fiscal year, 30 days ago: −$0.16 Next fiscal year, 7 days ago: −$0.14 Next fiscal year, Now: −$0.12 −$0.12

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.51−$0.22
60 days ago −$0.51−$0.22
30 days ago −$0.49−$0.16
7 days ago −$0.42−$0.14
Now −$0.43−$0.12

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.07 −$0.09 −20.0%
Mar 2026 −$0.12 −$0.17 −43.3%
Dec 2025 −$0.17 −$0.22 −26.9%
Sept 2025 −$0.25 −$0.29 −17.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy375%
Hold125%
Sell00%

Monthly trend

  1. Oct 2026314
  2. Sep 2026314
  3. Aug 2026314

Counts of recommendations published by analysts covering Outlook Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.2%
of tradable shares
Days to cover
6.98
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
25%
of shares
Held by insiders
12.6%
of shares
Employees
17
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OTLK+5%−21%−64%−76%−16%−70%
Industry peers (median)−36%−57%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OTLK42%50%33%42%58%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OTLK−62%−57%−89%−88%−71%−88%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 14, 2016: 100% from September 6, 2016 to March 24, 2026. Getting back needed a 437880% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.20 – $2.47
From 52-week high
−81.0%
vs 50-day average
−21.4%
vs 200-day average
−29.2%
Volatility (1 year)
152%
Beta vs S&P 500
1.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±8.8%
After a week
5 up, 7 down
typical move ±22.0%
After a month
5 up, 7 down
typical move ±108.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 −24.4% −0.7% −27.2% −24.3%
August 12, 2026 −21.3% +0.9% −38.9% −41.6%
May 18, 2026 0.0% −0.7% +75.4% +623.7%
May 13, 2026 −4.1% +1.4% +12.3% +402.1%
February 17, 2026 −16.3% +0.7% −16.1% −28.6%
December 19, 2025 −11.1% +1.5% −4.3% −75.4%
August 14, 2025 +9.9% −0.2% +13.1% −50.7%
May 15, 2025 +0.3% +1.1% −6.0% +1.4%
February 14, 2025 −7.1% +0.3% −17.4% −19.0%
December 27, 2024 +9.4% −2.2% +39.4% +18.8%
August 14, 2024 −0.9% +2.0% −6.2% −16.5%
May 15, 2024 −0.9% +1.0% +8.1% +3.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Outlook Therapeutics, Inc.
$0 $5M $10M FY17 Q1 FY17 Q4 FY18 Q3 FY19 Q4 Revenue (TTM), FY17 Q1: $2.3M Revenue (TTM), FY17 Q2: $1.6M Revenue (TTM), FY17 Q3: $1.4M Revenue (TTM), FY17 Q4: $3.8M Revenue (TTM), FY18 Q1: $4.3M Revenue (TTM), FY18 Q2: $4.7M Revenue (TTM), FY18 Q3: $5.2M Revenue (TTM), FY18 Q4: $3.1M Revenue (TTM), FY19 Q1: $3.4M Revenue (TTM), FY19 Q2: $3.3M Revenue (TTM), FY19 Q3: $3.1M Revenue (TTM), FY19 Q4: $8.1M $8.1M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY17 Q1 $2.3M
FY17 Q2 $1.6M
FY17 Q3 $1.4M
FY17 Q4 $3.8M
FY18 Q1 $4.3M
FY18 Q2 $4.7M
FY18 Q3 $5.2M
FY18 Q4 $3.1M
FY19 Q1 $3.4M
FY19 Q2 $3.3M
FY19 Q3 $3.1M
FY19 Q4 $8.1M
Revenue growth, TTM YoY Outlook Therapeutics, Inc.
-100% 0% 100% 200% 300% FY17 Q1 FY17 Q4 FY18 Q3 FY19 Q4 Revenue growth, TTM YoY, FY17 Q1: -30.2% Revenue growth, TTM YoY, FY17 Q2: -57.8% Revenue growth, TTM YoY, FY17 Q3: -52.9% Revenue growth, TTM YoY, FY17 Q4: 27.9% Revenue growth, TTM YoY, FY18 Q1: 87.1% Revenue growth, TTM YoY, FY18 Q2: 197.5% Revenue growth, TTM YoY, FY18 Q3: 271.6% Revenue growth, TTM YoY, FY18 Q4: -19.0% Revenue growth, TTM YoY, FY19 Q1: -21.0% Revenue growth, TTM YoY, FY19 Q2: -31.5% Revenue growth, TTM YoY, FY19 Q3: -41.3% Revenue growth, TTM YoY, FY19 Q4: 163.8% 163.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY17 Q1 -30.2%
FY17 Q2 -57.8%
FY17 Q3 -52.9%
FY17 Q4 27.9%
FY18 Q1 87.1%
FY18 Q2 197.5%
FY18 Q3 271.6%
FY18 Q4 -19.0%
FY19 Q1 -21.0%
FY19 Q2 -31.5%
FY19 Q3 -41.3%
FY19 Q4 163.8%
Operating margin (TTM) Outlook Therapeutics, Inc.
-4000% -3000% -2000% -1000% 0% FY17 Q1 FY17 Q4 FY18 Q3 FY19 Q4 Operating margin (TTM), FY17 Q1: -2304.8% Operating margin (TTM), FY17 Q2: -3609.7% Operating margin (TTM), FY17 Q3: -3056.4% Operating margin (TTM), FY17 Q4: -941.4% Operating margin (TTM), FY18 Q1: -496.8% Operating margin (TTM), FY18 Q2: -426.6% Operating margin (TTM), FY18 Q3: -386.0% Operating margin (TTM), FY18 Q4: -960.1% Operating margin (TTM), FY19 Q1: -1085.4% Operating margin (TTM), FY19 Q2: -1155.9% Operating margin (TTM), FY19 Q3: -1175.4% Operating margin (TTM), FY19 Q4: -445.6% -445.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q1 -2304.8%
FY17 Q2 -3609.7%
FY17 Q3 -3056.4%
FY17 Q4 -941.4%
FY18 Q1 -496.8%
FY18 Q2 -426.6%
FY18 Q3 -386.0%
FY18 Q4 -960.1%
FY19 Q1 -1085.4%
FY19 Q2 -1155.9%
FY19 Q3 -1175.4%
FY19 Q4 -445.6%
FCF margin (TTM) Outlook Therapeutics, Inc.
-3000% -2000% -1000% 0% FY17 Q1 FY17 Q4 FY18 Q3 FY19 Q4 FCF margin (TTM), FY17 Q1: -1756.9% FCF margin (TTM), FY17 Q2: -2339.3% FCF margin (TTM), FY17 Q3: -1890.7% FCF margin (TTM), FY17 Q4: -414.5% FCF margin (TTM), FY18 Q1: -456.8% FCF margin (TTM), FY18 Q2: -486.7% FCF margin (TTM), FY18 Q3: -500.4% FCF margin (TTM), FY18 Q4: -1160.2% FCF margin (TTM), FY19 Q1: -1066.8% FCF margin (TTM), FY19 Q2: -1066.5% FCF margin (TTM), FY19 Q3: -1189.2% FCF margin (TTM), FY19 Q4: -401.8% -401.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q1 -1756.9%
FY17 Q2 -2339.3%
FY17 Q3 -1890.7%
FY17 Q4 -414.5%
FY18 Q1 -456.8%
FY18 Q2 -486.7%
FY18 Q3 -500.4%
FY18 Q4 -1160.2%
FY19 Q1 -1066.8%
FY19 Q2 -1066.5%
FY19 Q3 -1189.2%
FY19 Q4 -401.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Sept 2015 2016 Sept 2016 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2025 Sept 2025
Income
Revenue 5 3 4 3 8 1
Gross profit — — — — — 0
EBITDA −45 −49 −33 −27 −33 −67
Operating income −47 −51 −36 −30 −36 −67
Net income −47 −53 −39 −30 −35 −62
Diluted EPS −$108.60 −$3.67 −$1.80 −$24.40 −$39.60 −$1.79
Growth (year on year)
Revenue — −42.9% +27.9% −19.0% +163.8% −82.6%
Margins
Gross margin — — — — — 4.0%
EBITDA margin −857.2% <−999% −870.7% −861.2% −404.3% <−999%
Operating margin −892.1% <−999% −941.4% −960.1% −445.6% <−999%
Net margin −908.0% <−999% <−999% −974.6% −423.8% <−999%
Free-cash-flow margin −695.1% <−999% −414.5% <−999% −401.8% <−999%
Cash flow
Cash from operations −27 −45 −16 −33 −32 −52
Capital spending 9 1 0 3 0 0
Free cash flow −36 −47 −16 −36 −33 −52
Stock-based pay 11 12 9 2 1 9
Free cash flow after stock pay −47 −59 −24 −38 −34 −61
Balance sheet
Cash 9 2 3 2 8 8
Total debt 17 7 5 5 — 30
Net debt (negative = net cash) 8 5 2 3 −8 22
Diluted shares — — 1m 2m — 35m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 2 checks passed · June 30, 2026
What it owns · $26m
Short-term assets $23mLonger-term assets $3m
What it owes, and who funded it · $37m
Short-term liabilities $29mLonger-term liabilities $8mShareholders' equity $-10m
  • Short-term assets cover short-term liabilities $23m of assets due within a year against $29m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $23m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Outlook Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated OTLK ACRS COYA APLM ADAG ROIV Median
Revenue, last 12 months $8m $8m $8m $9m $8m $8m $55m
Revenue growth, last 12 months 163.8% −51.0% >999% — >999% −67.6% 12.7%
Revenue growth, 3-year average 39.8% −35.9% — — — −46.4% 14.3%
Revenue growth, latest quarter 658.3% −8.3% 49.0% — — −33.5% 10.2%
Operating margin −445.6% <−999% −288.7% — −279.5% <−999% −191.1%
Operating margin, 3-year average −782.4% −711.4% <−999% — — −102.3% −365.3%
Net margin −423.8% −921.5% −270.2% −128.7% −229.6% <−999% −172.8%
Cash from operations / revenue −396.4% −755.1% −196.1% −122.0% −204.1% <−999% −168.8%
Free-cash-flow margin −401.8% −756.5% −196.3% −122.0% −204.3% <−999% −168.1%
Free-cash-flow margin, 3-year average −658.8% −339.9% <−999% — — <−999% −313.4%
Stock pay / revenue 16.1% 141.8% 66.3% −11.5% 48.8% >999% 19.2%
Change in share count 20.6% 25.5% 22.4% 41.8% 4.8% 0.6% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$32.5M
Institutions reporting
67
Shares held vs prior quarter
▲ 90.7%
Positions opened / closed
27 / 13

Top buyers and sellers, Q2 2026: 46 institutions bought and 20 sold ; the biggest buyer was Perceptive Advisors LLC (+3.1M shares) and the biggest seller Armistice Capital, LLC (−4.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $7M 4.4M 21.4% ▲ 122.5%
Perceptive Advisors LLC $5M 3.1M 15.3% New
Marshall Wace, LLP $3.2M 2.0M 9.7% New
Blackrock, Inc. $2.7M 1.7M 8.2% ▲ 249.5%
Jane Street Group, LLC $2.3M 1.4M 7.0% New
Geode Capital Management, LLC $2M 1.2M 6.1% ▲ 106.4%
Susquehanna International Group, LLP $1.5M 968K 4.7% ▲ 622.1%
HRT Financial LP $1.2M 785K 3.8% ▲ 1058.4%
Vanguard Fiduciary Trust Co $1.1M 662K 3.2% ▲ 274.8%
Gilpin Wealth Management, LLC $882,450 555K 2.7% ▼ 7.5%
State Street Corp $858,285 540K 2.6% ▲ 231.0%
Cantor Fitzgerald, L. P. $715,500 450K 2.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Outlook Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $7.9M 10 trades by 8 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $7.9M net buying
Insider Date Trade Shares Price Value
Kenyon Lawrence A Chief Financial Officer August 14, 2026 Buy 101,010 — $0
Jahr Robert Charles Chief Executive Officer August 14, 2026 Buy 151,515 — $0
Sukhtian Ghiath M. Director August 12, 2026 Buy 2,525,252 $0.99 $2.5M
Sukhtian Faisal Ghiath Director July 29, 2026 Buy 95,398 $1.05 $100,168
Haddadin Yezan Munther Director June 2, 2026 Buy 29,000 $0.83 $24,070
Gms Ventures & Investments Director May 28, 2026 Buy 8,539,709 $0.59 $5M
Sukhtian Faisal Ghiath Director May 27, 2026 Buy 122,174 $0.41 $50,091
Hilzinger Kurt J Director May 26, 2026 Buy 400,000 $0.44 $176,000
Thurman Randy H Director May 26, 2026 Buy 5,000 $0.43 $2,150
Haddadin Yezan Munther Director May 26, 2026 Buy 34,000 $0.44 $14,960

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 14, 2026
  • August 12, 2026
  • May 18, 2026
  • May 13, 2026
  • February 17, 2026
  • December 19, 2025

Recent SEC filings

Data status

When each part of this page on Outlook Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Outlook Therapeutics, Inc. in brief

What does Outlook Therapeutics, Inc. do?
Outlook Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in September.
What is Outlook Therapeutics, Inc.'s stock ticker?
Outlook Therapeutics, Inc. trades under the ticker OTLK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Outlook Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Perceptive Advisors LLC and Marshall Wace, LLP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Outlook Therapeutics, Inc.'s market cap?
On September 30, 2025, Outlook Therapeutics, Inc.'s market capitalisation was about $36.9M and net debt of $21.9M. Market figures come from third-party market data and may be delayed.
Who are Outlook Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Outlook Therapeutics, Inc. are Aclaris Therapeutics, Inc., Coya Therapeutics, Inc., Apollomics Inc., Adagene Inc. and Roivant Sciences Ltd. The side-by-side comparison below sets their revenue, margins and growth against Outlook Therapeutics, Inc.'s.
Are insiders buying or selling Outlook Therapeutics, Inc. stock?
Over the last 12 months, Outlook Therapeutics, Inc.'s directors and officers reported 10 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Outlook Therapeutics, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Outlook Therapeutics, Inc. announces its own schedule.